Utilization of epidermal growth factor receptor (EGFR) testing in the United States: A case study of T3 translational research

Genetics in Medicine

Volumn 15, Issue 8, 2013, Pages 630-638

  Lynch, Julie A ^a,c   Khoury, Muin J ^b   Borzecki, Ann ^c   Cromwell, Jerry ^a   Hayman, Laura L ^a   Ponte, Pat Reid ^d   Miller, Glenn A ^e,f   Lathan, Christopher S ^d  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e GENZYME GENETICS   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Dissemination and implementation; EGFR assay; Equity in access; Lung cancer genomics; T3 translation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BIOASSAY; CASE STUDY; COMMUNITY HOSPITAL; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; HEALTH CARE ACCESS; INCOME; LUNG CANCER; MOLECULAR DIAGNOSIS; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; THORAX SURGERY; TRANSLATIONAL RESEARCH; UNITED STATES;

CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; GENETIC TESTING; GENOMICS; GUIDELINES AS TOPIC; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84881319921     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.5     Document Type: Article

References (40)

1. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008;59: 1-12. (Pubitemid 351287920)
2. Tevak A, Kondratovich MV, Mansfield E. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Personalized Medicine 2010; 7(5): 517-530.
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12: 175-180.
4. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 2011;145: 19-24.
5. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet 2011;130: 3-14.
6. Auffray C, Caulfield T, Khoury MJ, Lupski JR, Schwab M, Veenstra T. Looking back at genomic medicine in 2011. Genome Med 2012;4(1):9.
7. National Cancer Institute. NCI community cancer centers program (NCCCP) fact sheet. http://ncccp.cancer.gov/Media/FactSheet.htm. Updated 2011. Accessed 3 August 2012.
8. Olson S, Berger AC. Roundtable on translating genomic-based research for health, Board on Health Sciences Policy, Institute of Medicine. Genome- Based Diagnostics: Clarifying Pathways to Clinical Use: Workshop Report. The National Academies Press, 2012. http://www.nap.edu/openbook.php?record- id=13359.
9. Hernandez LM. Institute of Medicine (U.S.). Roundtable on translating genomicbased research for health. Institute of Medicine (U.S.). Board on Health Sciences Policy. Diffusion and Use of Genomic Innovations in Health and Medicine: Workshop Summary. Updated 2008. National Academies Press: Washington, DC.
10. Fiore LD, D'Avolio LW. Detours on the road to personalized medicine: barriers to biomarker validation and implementation. JAMA 2011;306: 1914-1915.
11. Carpenter WR, Meyer AM, Wu Y, et al. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Med Care 2012;50: 737-748.
12. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 2011;13: 349-355.
13. Woolf SH. The meaning of translational research and why it matters. JAMA 2008;299: 211-213.
14. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9: 665-674. (Pubitemid 350287151)
15. Schully SD, Benedicto CB, Khoury MJ. How can we stimulate translational research in cancer genomics beyond bench to bedside? Genet Med 2012;14: 169-170.
16. Welch HG, Sharp SM, Gottlieb DJ, Skinner JS, Wennberg JE. Geographic variation in diagnosis frequency and risk of death among Medicare beneficiaries. JAMA 2011;305: 1113-1118.
17. Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C. National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health 2012;102: 1274-1281.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139. (Pubitemid 38637993)
19. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
20. Genzyme Genetics. Genzyme launches exclusive lung cancer test. http://www. genzyme.com/corp/investors/GENZ%20PR-092705.asp. Accessed 4 December 2011.
21. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008;15: 241-247.
22. Yost J. CLIA and genetic testing oversight. http://www.genome.gov/Pages/ About/OD/ReportsPublications/June2008-YostHoL.pdf. Published August 2011. Updated 2008. Accessed 12 August 2012.
23. Ettinger DS, Akerley W, Bepler G, et al.; NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8: 740-801.
24. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(suppl 5):S1-32; quiz S33.
25. ASCO. Provisional clinical opinion recommending EGFR mutation testing prior to use of first line targeted drugs for advanced lung cancer. http://www.asco. org/ASCOv2/Press+Center/Latest+News+Releases/ASCO+News/ ASCO+Issue s+Provisional+Clinical+Opinion+Recommending+EGFR+Mutation+Testing+ Prior+to+Use+of+First-Line+Targeted+Drugs+for+Advanced+Lung+Cancer. Updated 2011. Accessed 30 September 2011.
26. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21: 2237-2246. (Pubitemid 46621858)
27. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29: 2066-2070.
28. Li E. NCCN trends™ survey and data: EGFR mutation testing practices. http:// www.nccn.org/about/news/ebulletin/2010-11-01/patient- advocacy.asp. Updated 2010. Accessed February 2011.
29. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11: 2106-2110. (Pubitemid 40490166)
30. Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009;27: 5620-5626.
31. Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 2006;24: 413-418. (Pubitemid 46630461)
32. Cote ML, Haddad R, Edwards DJ, et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol 2011;6: 627-630.
33. Reinersman JM, Johnson ML, Riely GJ, et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011;6: 28-31.
34. Onega T, Duell EJ, Shi X, Demidenko E, Goodman D. Influence of place of residence in access to specialized cancer care for African Americans. J Rural Health 2010;26: 12-19.
35. Lynch J, Lathan C. Differences in utilization of ALK rearrangement FISH analysis and EGFR assay. J Clin Oncol 2012;30(suppl; abstr e18067).
36. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291: 2720-2726. (Pubitemid 38725421)
37. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304: 967-975.
38. Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature 2012;489(7414): 52-55. http://dx.doi. org/10.1038/489052a.
39. Centers for Disease Control and Prevention and National Cancer Institute. CancerGEM KB. Cancer genomic evidence-based medicine knowledge base website. http://www.hugenavigator.net/CancerGEMKB/home.do. Updated 2012. Accessed 12 August 2012.
40. Khoury MJ, Clauser SB, Freedman AN, et al. Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 2011;20: 2105-2114.